TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04743401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-exergaming Tablet
Description: The Tele-Exergame platform virtually supervises exercise tasks and coaches patients to perform evidence-based foot and ankle exercises that have been designed to improve balance, cognition, and lower extremity vascular health.~The exergame program uses a game-based approach, similar to playing a video game, which helps to increase patient motivation and engagement in the cognitively demanding exercise program.
Study: NCT05488925

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin E
Description: Evion, 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium
Description: Voltral SR100, 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piroxicam
Description: Feldene, 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Tramal, 50 mg
Study: NCT04516941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban Tablets
Description: Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban Tablets
Description: Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine Tablets
Description: Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine Tablets
Description: Treatment
Study: NCT05751161

Intervention type: OTHER
Group type: OTHER
Intervention: conventional gait training
Description: The experimental group received circuit gait training with auditory stimuli using a smartphone metronome application. The training program consisted of eight different activities i.e. tandem walk, one-leg standing, military march, sitting up and forward walk, lateral walk, kicking a ball towards the wall, walking on a set pattern and obstacle walk .Patient will practice each task for 3-4 mints and three times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional gait training
Description: The experimental group received circuit gait training with auditory stimuli using a smartphone metronome application. The training program consisted of eight different activities i.e. tandem walk, one-leg standing, military march, sitting up and forward walk, lateral walk, kicking a ball towards the wall, walking on a set pattern and obstacle walk .Patient will practice each task for 3-4 mints and three times per week.
Study: NCT05557136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multistranded stainless steel fixed retainer
Description: Multistranded stainless steel fixed retainer is used for orthodontic patient after completion of orthodontic treatment to achieve stability of alignment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyether-Ether-Ketone (PEEK) fixed retainer
Description: Polyether-Ether-Ketone (PEEK) fixed retainer is used for orthodontic patient after completion of orthodontic treatment to achieve stability of alignment.
Study: NCT05113810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ01
Description: HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care (SOC) for COVID-19
Description: Standard of care (SOC) for COVID-19
Study: NCT05832359

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Panoramic rad.
Description: In the study, digital panoramic x-rays of the patients will be evaluated and dental age estimation with Willems method and mandibular bone morphometric measurements will be made.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Panoramic rad.
Description: In the study, digital panoramic x-rays of the patients will be evaluated and dental age estimation with Willems method and mandibular bone morphometric measurements will be made.
Study: NCT01168375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy plus umbilical cord serum eye drop
Description: chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours plus umbilical cord serum eye drop 20% every 4 hours
Study: NCT05273372

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment with the food white rice flour. 1,000 mg BID

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Food - Anhydrous Enol-Oxaloacetate
Description: Active treatment with oxaloacetate. 1,000 mg BID
Study: NCT01168375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
Study: NCT05512845

Intervention type: PROCEDURE
Intervention: Double Factor technique
Description: The double factor computer assisted surgery technique, involves the combination of the static and dynamic computer assisted surgery protocols to place dental implants in the same surgery.
Study: NCT05758051

Intervention type: PROCEDURE
Group type: OTHER
Intervention: subtrochanteric valgus osteotomy
Description: subtrochanteric valgus osteotomy
Study: NCT05394181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Notification
Description: Notification of patient and primary care clinician of presence of at least moderate coronary artery calcium on a prior non-gated chest CT
Study: NCT00962481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimosiamose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06367049

Intervention type: DIAGNOSTIC_TEST
Intervention: Methylation-specific PCR
Description: Methylation-specific PCR is the simplest and quickest method for qualitative detection of methylation status.~The unmethylated C base is converted to U by bisulfite conversion, which is subsequently amplified by PCR with primers (methylation-specific and non-methylation-specific primers) and subsequently detected by agarose gel electrophoresis or a probe. The key to MSP is to design PCR primers for specific gene regions. The research team of this project has previously found the sequence sites of methylation of H4C6, Septin9 and RASSF1A genes in nasopharyngeal carcinoma tissues through methylation sequencing, and designed specific MSP amplification primers and probes accordingly, which can perform methylation detection easily and quickly.

Intervention type: DIAGNOSTIC_TEST
Intervention: Methylation-specific PCR
Description: Methylation-specific PCR is the simplest and quickest method for qualitative detection of methylation status.~The unmethylated C base is converted to U by bisulfite conversion, which is subsequently amplified by PCR with primers (methylation-specific and non-methylation-specific primers) and subsequently detected by agarose gel electrophoresis or a probe. The key to MSP is to design PCR primers for specific gene regions. The research team of this project has previously found the sequence sites of methylation of H4C6, Septin9 and RASSF1A genes in nasopharyngeal carcinoma tissues through methylation sequencing, and designed specific MSP amplification primers and probes accordingly, which can perform methylation detection easily and quickly.
Study: NCT05973292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resin cement containing phosphate ester monomer 10-methacryloyloxydecyl dihydrogen phosphate
Description: Adhesive resin cement containing an MDP agent that is added to bonding agents to enhance bonding to ceramics like Ziconia and E-max

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non MDP containg resin cement
Description: Adhesive resin cement not containing an MDP agent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non MDP containg resin cement
Description: Adhesive resin cement not containing an MDP agent
Study: NCT04962152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine Sebacate or Sesame oil (placebo)
Description: ultrasound-guided intramuscular injection after the induction of anesthesia immediately

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nalbuphine Sebacate or Sesame oil (placebo)
Description: ultrasound-guided intramuscular injection after the induction of anesthesia immediately
Study: NCT06281600

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharide
Description: 5g daily dose of HMOs.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin placebo
Description: 5g daily dose of maltodextrin.
Study: NCT04555291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of ropivacaïne 2 mg/ml

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NACL
Description: Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of NACL
Study: NCT06065943

Intervention type: OTHER
Group type: OTHER
Intervention: Palpation and Fluoroscopy
Description: Vessel puncture guided palpation and fluoroscopy only

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guidance
Description: Vessel puncture guided by Ultrasound
Study: NCT05862480

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Spray with Hypochlorous Acid Group
Description: For Each Patient included . A prescription of a nasal spray in each nostril/3 hours and two oral sprays/3 hours by a solution of hypochlorous acid (NEED DEFENDER) for 5 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spray with Placebo Group
Description: For Each Patient included , A prescription of an identical to the intervention nasal spray in each nostril/3 hours and two oral sprays/3 hours by Placebo for 5 days.
Study: NCT04890769

Intervention type: DEVICE
Intervention: Moisture sensor wound dressing
Description: Clinical procedure for change of wound dressing
Study: NCT04856371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYH33
Description: Participants will receive oral CYH33 once daily on Days 1-28 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYH33
Description: Participants will receive oral CYH33 once daily on Days 1-28 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYH33
Description: Participants will receive oral CYH33 once daily on Days 1-28 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1, 15 on Cycle 1 (28-day cycle) and Day 1 at each 28-day cycle thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1, 15 on Cycle 1 (28-day cycle) and Day 1 at each 28-day cycle thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Participants will receive oral letrozole once daily continuous on Day 1-28 of each cycle.
Study: NCT06026423

Intervention type: OTHER
Intervention: Clinical examination and pictures
Description: A clinical examination is needed to assess the healing process for the three groups. After assessing the healing process, we will take pictures of the tear for documentation.

Intervention type: OTHER
Intervention: Clinical examination and pictures
Description: A clinical examination is needed to assess the healing process for the three groups. After assessing the healing process, we will take pictures of the tear for documentation.

Intervention type: OTHER
Intervention: Clinical examination and pictures
Description: A clinical examination is needed to assess the healing process for the three groups. After assessing the healing process, we will take pictures of the tear for documentation.

Intervention type: OTHER
Intervention: Questionnaire
Description: The participant will answer questions, serving as a baseline questionnaire, when arriving at the clinical examination one month post-partum. At three and 9-12 months post-postpartum, they will receive another questionnaire. The questionnaire will consist of validated questions regarding body image, pain, Urogynecological problems as symptoms of prolapse, urinary and anal incontinence, and questions about sexual problems.

Intervention type: OTHER
Intervention: Questionnaire
Description: The participant will answer questions, serving as a baseline questionnaire, when arriving at the clinical examination one month post-partum. At three and 9-12 months post-postpartum, they will receive another questionnaire. The questionnaire will consist of validated questions regarding body image, pain, Urogynecological problems as symptoms of prolapse, urinary and anal incontinence, and questions about sexual problems.

Intervention type: OTHER
Intervention: Questionnaire
Description: The participant will answer questions, serving as a baseline questionnaire, when arriving at the clinical examination one month post-partum. At three and 9-12 months post-postpartum, they will receive another questionnaire. The questionnaire will consist of validated questions regarding body image, pain, Urogynecological problems as symptoms of prolapse, urinary and anal incontinence, and questions about sexual problems.
Study: NCT04856371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Participants will receive palbociclib once daily continuous on Day 1-21 of each 28-day cycle.
Study: NCT06445010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creating Musical Playlist
Description: Personal music playlist for therapeutic listening and sharing with other individuals in bereavement
Study: NCT03749850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTLD
Description: Patients will receive up to six cycles at three-weeks intervals of:~* Intravenous LTLD dosed at 50mg/m2 administered during the MR-HIFU treatment~* 60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour~* Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, LTLD, cyclophosphamide and/or hyperthermia dosages will be adjusted as specified in the study protocol.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR-HIFU induced hyperthermia
Description: Patients will receive up to six cycles at three-weeks intervals of:~- 60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour.~In case of toxicity, hyperthermia dosages will be adjusted as specified in the study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will receive up to six cycles at three-weeks intervals of:~- Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, cyclophosphamide dosages will be adjusted as specified in the study protocol.
Study: NCT06004089

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: V NOTES Sacrocolpopexy
Description: The procedure involved a single-port laparoscopic surgery through the vaginal route, aiming to restore pelvic floor function by suspending the vagina to the anterior longitudinal ligament. The surgical approach differs from conventional methods, as these procedures are conducted through abdominal or vaginal routes without the aid of laparoscopic cameras, However, in our approach, we uniquely combine the widely acknowledged gold standard sacrocolpopexy procedure using vaginal route with laparoscopic camera assistance. No experimental drugs or devices were employed; only the surgical approach was modified.
Study: NCT06261385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: typology-based intervention
Description: A typology-based intervention delivered by smoking cessation (SC) counsellors to prevent smoking relapse in ex-smokers who recently quit
Study: NCT04776096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine Besilate 1.5% PF
Description: Bepotastine besilate 1,5% Preservative free ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine Hydrochloride 0.2% BAK
Description: Olopatadine hydrochloride 0.2% with BAK as preservative
Study: NCT06267300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: Hyperbaric oxygen therapy (2.4 ATA, 40 sessions)
Study: NCT04724213

Intervention type: OTHER
Group type: OTHER
Intervention: Testing of reliability / validity of new questionnaire
Description: Participants will answer new questionnaire and other, established, generic and chronic generic HrQol instruments
Study: NCT04971980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hUC-MSC infusion (BC-U001)
Description: The participants are intravenously administered a single infusion of hUC-MSC at 0.5x10\^6 cells/kg body weight, 1.0x10\^6 cells/kg body weight, 1.5x10\^6 cells/kg body weight for low-dose cohort, medium-dose cohort and high-dose cohort respectively.
Study: NCT06398665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta-Burst Stimulation
Description: Accelerated course of left dlPFC iTBS, consisting of 600 pulses/session, 50 minutes intersession interval, 8 session/day for 5 days) at 90% resting motor threshold (MT)
Study: NCT05316350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram recording
Description: ECG recording with investigational device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram recording
Description: ECG recording with investigational device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram recording
Description: ECG recording with reference device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram recording
Description: ECG recording with reference device
Study: NCT06107374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-AraG
Description: Two PET scans
Study: NCT06369753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Three sessions of biofeedback intervention will be performed during the first 3 weeks of the intervention period. Patients will be taught to control abdominal and thoracic muscular activity by providing instructions using an original video support. Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three sessions of placebo intervention will be performed during the first 3 weeks of the intervention period. Sham measurements of abdominal and thoracic motion will be performed, and a pill of placebo containing 0.21 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
Study: NCT05966090

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA investigational vaccine
Description: One dose of RSVPreF3 OA investigational vaccine given intramuscularly on Day 1 (Coadministration group) or Day 31 (Control group).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSVPreF3 OA investigational vaccine
Description: One dose of RSVPreF3 OA investigational vaccine given intramuscularly on Day 1 (Coadministration group) or Day 31 (Control group).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HZ/su vaccine
Description: Two doses of HZ/su vaccine given intramuscularly on Day 1 and Day 61.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HZ/su vaccine
Description: Two doses of HZ/su vaccine given intramuscularly on Day 1 and Day 61.
Study: NCT06268184

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D3 LAB SYRUP
Description: omega 3 suplementation
Study: NCT06505668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol 25 mg
Description: Patients will be receiving Atenolol 25mg OD for 2 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine 10mg
Description: Patients will be receiving Ivabradine 5mg BD for 2 months.
Study: NCT05199012

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Black pepper extract
Description: Subjects will be randomized to receive either the placebo or active (black pepper extract) in a 1:1

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Black pepper extract
Description: Subjects will be randomized to receive either the placebo or active (black pepper extract) in a 1:1
Study: NCT06268184

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo syrup
Description: placebo syrup contains purified water, glycerin, xanthan gum, tween 80, methyl paraben, propyl paraben, sorbitol solution70% and apple flavor.
Study: NCT05574790

Intervention type: OTHER
Intervention: annual follow up
Description: Collection of the following information during the year following discharge from the initial episode (initial cohort): readmissions, dates and causes of readmission, mortality
Study: NCT06324539

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test: Rapid Intestinal anti-TG2 Assay
Description: Evaluation of the reliability of the Rapid Intestinal anti-TG2 Assay for revealing anti-TG2 antibodies in duodenal biopsy specimens of patients suffering from CD, especially potential CD in which the diagnosis may be challenging.~Intestinal anti-TG2 will be investigated also in patients suffering from other non-CD related gastrointestinal disorders. Sensitivity, specificity and likelihood ratios of the Rapid Intestinal anti-TG2 assay will be calculated and compared to the reference standard (serology + histopathology) of CD diagnosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test: Rapid Intestinal anti-TG2 Assay
Description: Evaluation of the reliability of the Rapid Intestinal anti-TG2 Assay for revealing anti-TG2 antibodies in duodenal biopsy specimens of patients suffering from CD, especially potential CD in which the diagnosis may be challenging.~Intestinal anti-TG2 will be investigated also in patients suffering from other non-CD related gastrointestinal disorders. Sensitivity, specificity and likelihood ratios of the Rapid Intestinal anti-TG2 assay will be calculated and compared to the reference standard (serology + histopathology) of CD diagnosis.
Study: NCT06467786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride liposome injection
Description: Irinotecan hydrochloride liposome injection combined with platinum
Study: NCT05302804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menthol Gel
Description: 5% menthol gel applied from shoulder to wrist and mid thigh to ankle, 30 minute treadmill walk (3.5 mph at 5% grade at 38°C, 60% relative humidity)
Study: NCT05741632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Ophthalmic Solution
Description: Moxifloxacin solution 0.1 cc undiluted, self preserved, injected into intracamera at the end of cataract surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin Ophthalmic
Description: Levofloxacin solution 0.1 cc undiluted, self preserved, injected into intracamera at the end of cataract surgery